CIMA LAB Diagnostics obtains once again the endorsement of the external quality assessment of the European Molecular Quality Network (EMQN).
The approval obtained is for the study of biomarkers in solid tumours, as well as germline alterations, by Next Generation Sequencing (NGS).
The laboratory Solid Tumours and Hereditary Diseases of CIMA LAB Diagnostics has successfully participated in four intercomparison programmes promoted by the European Molecular Quality Network(EMQN), as part of external quality assurance monitoring.
These intercomparison programmes evaluate both the technical capacity of NGS sequencing for the detection of somatic and germline variants, and the identification and clinical interpretation of somatic variants in BRCA1/ BRCA2 in ovarian carcinomas and other biomarkers with clinical utility in solid tumours(EGFR, NRAS, KIT, BRAF, TP53, KRAS and PIK3CA).
About EMQNIt is a non-profit Community Interest Company (CIC) that promotes quality in genetic testing by establishing, harmonising and disseminating best practices in laboratories.